Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

• TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications
  
  
• Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-up
  
  
• Proof-of-concept demonstrated for non-viral Sleeping Beauty cell engineering platform in effective manufacturing of TCR-T cell therapies with all products achieving >90% TCR positivity
  
  
• Data to be presented on Saturday, June 3, at 8:00 a.m. CT
  

HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present early translational data from the first three patients treated in its ongoing TCR-T Library Phase 1/2 trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.

“Demonstrating our first objective clinical response in solid tumors using non-viral TCR-T cell therapy establishes proof-of-concept of our Sleeping Beauty cell engineering platform’s potential to generate safe, persistent and effective TCR-T therapies,” said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. “We believe our innovative non-viral approach targeting high-frequency driver mutations is the most promising approach for treating solid tumors. We are encouraged by our ability to manufacture cell products with high viability, purity and TCR positivity that have exhibited persistence and tumor infiltration in patients. We remain confident in the promise of our TCR-T platform to weaponize the immune system and revolutionize the treatment of solid tumors.”

The poster will highlight early clinical and translational data on the first three patients with refractory solid tumors expressing KRAS or TP53 mutations who received Sleeping Beauty TCR-T cells at one of two dose levels, DL1 (0.9 x 10¹⁰ TCR-T cells) and DL2 (6.4 x 10¹⁰ TCR-T cells and 5.8 x 10¹⁰ TCR-T cells). Manufactured TCR-T cells exhibited greater than 90% TCR positivity, viability and purity, underscoring the ability of the Company’s non-viral, universal manufacturing process to create TCR-T cells in multiple indications with different TCRs.